MAP LC3β Inhibitors

MAP LC3β inhibitors, also known as microtubule-associated protein light chain 3 beta inhibitors, constitute a class of chemical compounds that target a key element within the cellular process of autophagy. Autophagy, a tightly regulated catabolic pathway, plays a vital role in cellular homeostasis by facilitating the degradation of dysfunctional cellular components and recycling their constituents. LC3β, a protein associated with autophagosome membrane formation, is an essential component of the autophagic process. These inhibitors interact with LC3β and modulate its function, thereby influencing the progression of autophagy. The mechanism of action of MAP LC3β inhibitors primarily centers around their ability to disrupt the intricate molecular machinery involved in autophagosome formation and maturation. These inhibitors can target various stages of the autophagy pathway, exerting their effects by impeding LC3β's engagement in autophagosome biogenesis. Some inhibitors may interact directly with LC3β, altering its conformation and affecting its interaction with other proteins crucial for autophagosome initiation. Others might interfere with upstream signaling pathways that regulate LC3β recruitment, indirectly inhibiting its involvement in autophagy.

Additionally, some MAP LC3β inhibitors may hinder the fusion of autophagosomes with lysosomes, where degradation occurs, leading to an accumulation of undegraded cargo. MAP LC3β inhibitors exhibit a diverse range of chemical structures, reflecting the versatility of approaches to modulating autophagy.